PACB Pacific Biosciences of California, Inc. - Common Stock
NASDAQ · Life Sciences Tools & Services · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 6, 2026
$2,54
· % zakresu 52 tyg.
· powyżej minimum
· do maksimum
$1,0752tyg. minimum
$2,7352tyg. maksimum
Kapitalizacja Rynkowa (MRQ)
$789M
P/E (TTM)
-6.2
EPS (TTM)
$-0.41
Przychody (TTM)
$159M
Twoje odznaki
Zakres 52 tyg.
$1–$3
Ocena Analityków
BUY
Cena Docelowa
$2
P/E
-6.2
ROE
-929.3%
Marża Zysku Netto
-82.5%
Twój pasek odznak jest pusty — przypnij metrykę w dowolnym miejscu na tej stronie.
PACB Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$2.54
Kapitalizacja Rynkowa (MRQ)
$789M
P/E (TTM)
-6.2
EPS (TTM)
$-0.41
Przychody (TTM)
$159M
ROE (TTM)
-929.3%
Zakres 52 tyg.
$1–$3
PACB Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
zakres
kreski
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
O Pacific Biosciences of California, Inc. - Common Stock Przegląd firmy z Wikipedii
Pacific Biosciences of California, Inc. (a.k.a. PacBio) is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
History
The company was founded based on research done at Cornell University that combined semiconductor processing and photonics with biotechnology research. Three graduate students in the lab of Professors Watt W. Webb — Jonas Korlach — and Harold Craighead — Steve Turner and Mathieu Foquet — became the first employees.
It began under the name Nanofluidics, Inc. The company raised nearly US$400,000,000 in six rounds of primarily venture capital financing, making it one of the most capitalized startups in 2010 leading up to their public offering in October of that year. Key investors included Mohr Davidow Ventures, Kleiner, Perkins, Caufield & Byers, Alloy Ventures, and Wellcome Trust.
The company's first commercial product, the PacBio RS, was sold to a limited set of customers in 2010 and was commercially released in early 2011. A subsequent version of the sequencer called the PacBio RS II was released in April 2013.
Leadership
In 2004, Kleiner Perkins entrepreneur-in-residence Hugh Martin became CEO. On 6 January 2012 board member Michael Hunkapiller, PhD assumed the role of CEO. Hunkapiller retired in September 2020, and was replaced by chairman of the board Christian Henry. Henry was a former executive VP and chief commercial officer of Illumina before joining the board at PacBio in July 2018.
Illumina: attempted acquisition
On 1 November 2018, Illumina, Inc. agreed to purchase PacBio for US$1.2 billion in cash. The deal was expected to close in the fourth quarter of 2019. In December 2019, the Federal Trade Commission sued to block the acquisition. The deal was abandoned with an announcement on 2 January 2020. Illumina further agreed to pay Pacific Biosciences a $98 million US termination fee plus previously agreed upon deal extension payments of $22 million US in February and $6 million US in March 2020.
Sequencing technology
Sequencing instruments
The company's first scientific instrument, called the PacBio RS, was released to a limited set of customers in late 2010., with full commercial release in early 2011. Sequencing provider GATC Biotech was selected by Pacific Biosciences as its first European service provider in late 2010. A new version of the sequencer was released in April 2013 it produced longer sequence reads and higher throughput than the original RS instrument. The RS instrument will officially be supported until the end of 2021. In September 2015, the company released a new sequencing instrument, the Sequel System, with increased sequencing capacity at a smaller size and lower price compared to the PacBio RS II. Subsequently, in October 2022, PacBio launched a new sequencing system, which can sequence 1,300 human genomes per year as compared to 86 per year of the previous PacBio sequencing machines.
Reagents and SMRT Cells
To use either instrument, customers must also purchase reagent packs for DNA preparation and sequencing and small consumables called "SMRT Cells." Cells for early forms of the sequencer are slightly less than one-centimeter square and contains tens of thousands of zero-mode waveguides, whereas newer systems have a higher density of cells and contain 25 million zero-mode waveguides (ZMWGs), allowing for faster DNA sequencing.
Software and applications
Their secondary analysis bioinformatics product for the RS, called “SMRT Analysis”, was open source. For the Sequel system the secondary analysis software was reorganized as the "SMRT Link" application. In 2013, the company released new bioinformatics tools for automated genome assembly (HGAP) and finishing (Quiver).
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
sektorHealthcare
branżaLife Sciences Tools & Services
pracownicy485
krajUS
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody$160M2016-12-31 → 2025-12-31
EPS$-1.822018-12-31 → 2025-12-31
Wolny przepływ pieniężny$-114M2016-12-31 → 2025-12-31
Marża netto-82.5%2016-12-31 → 2025-12-31
Wycena i wskaźniki
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | PACB | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | -6.2średnia z 5 lat ≈-7.8 | ≈-7.8 | · | · | |
| P/S (TTM) | 5.0średnia z 5 lat ≈13.8 | ≈13.8 | 4.6 | Niedowartościowany | |
| P/B (MRQ) | -23.8średnia z 5 lat ≈23.9 | ≈23.9 | · | · | |
| Cena / FCF (TTM) | -6.4średnia z 5 lat ≈-12.5 | ≈-12.5 | · | · | |
| Cena / Przepływy pieniężne (TTM) | -6.7średnia z 5 lat ≈-13.1 | ≈-13.1 | · | · | |
| Cena / Wartość księgowa materialna (MRQ) | -17.1 | · | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | PACB | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża brutto (TTM) | 36.4%średnia z 5 lat ≈32.5% | ≈32.5% | 46.6% | Słaby | |
| Marża Operacyjna (TTM) | -83.5%średnia z 5 lat ≈-244.3% | ≈-244.3% | -22.1% | Słaby | |
| EBITDA Margin (Marża EBITDA) | -346.1%średnia z 5 lat ≈-244.3% | ≈-244.3% | -22.1% | Słaby | |
| Marża przed opodatkowaniem (TTM) | -82.0%średnia z 5 lat ≈-231.3% | ≈-231.3% | -15.3% | Słaby | |
| Marża Zysku Netto (TTM) | -82.5%średnia z 5 lat ≈-215.9% | ≈-215.9% | -21.1% | Słaby | |
| ROA (TTM) | -16.7%średnia z 5 lat ≈-24.6% | ≈-24.6% | -8.3% | Słaby | |
| ROE (TTM) | -929.3%średnia z 5 lat ≈-363.3% | ≈-363.3% | -10.9% | Słaby | |
| ROIC | -10360.5%średnia z 5 lat ≈-2629.4% | ≈-2629.4% | -16.2% | Słaby |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | PACB | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Wskaźnik bieżący (MRQ) | 4.9średnia z 5 lat ≈7.8 | ≈7.8 | 4.5 | Silna płynność | |
| Wskaźnik Szybkości (MRQ) | 3.9średnia z 5 lat ≈7.1 | ≈7.1 | 1.7 | Silna płynność |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | PACB | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | 3.9%średnia z 5 lat ≈20.1% | ≈20.1% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 7.6%średnia z 5 lat ≈16.6% | ≈16.6% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 15.2% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | PACB | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 0.2średnia z 5 lat ≈0.1 | ≈0.1 | 0.3 | Słaby | |
| Inventory Turnover (Rotacja zapasów) | 2.1średnia z 5 lat ≈2.5 | ≈2.5 | 3.5 | Słaby | |
| Receivables Turnover (Rotacja należności) | 5.1średnia z 5 lat ≈5.9 | ≈5.9 | 5.8 | Słaby | |
| Revenue / Employee (Przychody / pracownika) | ≈$329.9K | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
-97.7%
Następny raport
Lis 03, 2026
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 3, 2026 | $-0.14 | $-0.13 | -7.9% |
| 31 marca 2026 | $-0.12 | $-0.14 | 12.7% | |
| 31 grudnia 2025 | $-0.12 | $-0.15 | 20.3% | |
| 30 września 2025 | $-0.13 | $-0.15 | 16.1% | |
| 30 czerwca 2025 | $-0.14 | $-0.17 | 19.3% | |
| 31 marca 2025 | $-1.44 | $-0.19 | -646.9% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $160M | $154M | $201M | $128M | $131M | $79M | $91M | $79M | $93M | $91M | $93M | $61M | |
| Cost of Revenue | $114M | $117M | $148M | $79M | $72M | $46M | $56M | $54M | $59M | $47M | $39M | $37M | |
| Gross Profit | $46M | $37M | $53M | $49M | $59M | $33M | $35M | $25M | $35M | $44M | $53M | $23M | |
| R&D Expense | $97M | $135M | $187M | $193M | $113M | $64M | $60M | $63M | $65M | $68M | $60M | $48M | |
| SG&A Expense | $141M | $175M | $170M | $161M | $124M | $73M | $75M | $63M | $59M | $48M | $45M | $38M | |
| Operating Expenses | $600M | $512M | $387M | $356M | $269M | $137M | $135M | $126M | $124M | $115M | $83M | $86M | |
| Operating Income | $-554M | $-474M | $-334M | $-307M | $-210M | $-104M | $-101M | $-101M | $-90M | $-71M | $-29M | $-63M | |
| Interest Expense | · | · | $14M | $15M | $13M | $267.0K | $3M | $2M | $3M | $3M | $3M | $3M | |
| Other Non-op | $15M | $24M | $33M | $8M | $93.0K | $2M | $1M | $848.0K | $516.0K | $103.0K | $364.0K | $-478.0K | |
| Pretax Income | $-546M | $-310M | $-318M | $-314M | $-275M | $29M | $-84M | · | · | · | · | · | |
| Income Tax | $318.0K | $316.0K | $-11M | $0 | $-94M | · | · | · | · | · | · | · | |
| Net Income | $-546M | $-310M | $-307M | $-314M | $-181M | $29M | $-84M | $-103M | $-92M | $-74M | $-32M | $-66M | |
| EPS (Basic) | $-1.82 | $-1.13 | $-1.21 | $-1.40 | $-0.89 | $0.18 | $-0.55 | $-0.76 | · | · | · | · | |
| EPS (Diluted) | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 | $0.17 | $-0.55 | $-0.76 | · | · | · | · | |
| Shares (Basic) | 299,959,000 | 274,488,000 | 253,629,000 | 224,550,000 | 204,136,000 | 165,187,000 | 152,527,000 | 135,094,000 | · | · | · | · | |
| Shares (Diluted) | 299,959,000 | 288,366,000 | 253,629,000 | 224,550,000 | 204,136,000 | 174,970,000 | 152,527,000 | 135,094,000 | · | · | · | · | |
| EBITDA | $-554M | $-474M | $-334M | $-307M | $-210M | $-104M | $-101M | $-94M | $-81M | $-67M | $-25M | $-59M |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $64M | $55M | $180M | $325M | $461M | $82M | $30M | $19M | $17M | $17M | $34M | $36M | |
| Short-term Investments | $216M | $335M | $452M | $447M | $584M | $237M | $19M | $84M | $46M | $55M | $49M | $65M | |
| Receivables | $35M | $28M | $37M | $19M | $24M | $17M | $15M | $9M | $13M | $11M | $5M | $3M | |
| Inventory | $49M | $59M | $57M | $50M | $25M | $14M | $13M | $18M | $23M | $16M | $11M | $11M | |
| Prepaid Expense | $11M | $19M | $17M | $10M | $7M | $5M | $3M | $3M | $2M | $10M | $12M | $2M | |
| Other Current Assets | · | · | · | · | · | · | · | · | $931.0K | $476.0K | $741.0K | $107.0K | |
| Current Assets | $375M | $496M | $742M | $852M | $1.10B | $356M | $81M | $132M | $102M | $109M | $111M | $118M | |
| PP&E (Net) | $24M | $31M | $36M | $42M | $33M | $25M | $30M | $34M | $38M | $15M | $9M | $7M | |
| PP&E (Gross) | $117M | $112M | $111M | $107M | $89M | $75M | $74M | $71M | $70M | $52M | $42M | $37M | |
| Accum. Depreciation | $92M | $82M | $75M | $65M | $56M | $50M | $44M | $37M | $32M | $37M | $34M | $30M | |
| Goodwill | $318M | $318M | $462M | $410M | $410M | · | · | · | · | · | · | · | |
| Intangibles | $15M | $390M | $457M | $410M | $411M | · | · | · | · | · | · | · | |
| Other Non-current Assets | $9M | $9M | $13M | $11M | $1M | $43.0K | $42.0K | $43.0K | $45.0K | $10M | $8M | $29.0K | |
| Total Assets | $784M | $1.26B | $1.75B | $1.77B | $2.01B | $414M | $148M | $170M | $144M | $138M | $131M | $124M | |
| Accounts Payable | $21M | $17M | $15M | $12M | $11M | $4M | $8M | $7M | $9M | $8M | $5M | $6M | |
| Accrued Liabilities | $34M | $23M | $46M | $33M | $36M | $17M | $13M | $13M | $13M | $17M | $16M | $11M | |
| Short-term Debt | · | $0 | $490.0K | $2M | $2M | · | $16M | · | · | · | · | · | |
| Current Liabilities | $73M | $66M | $95M | $263M | $72M | $39M | $49M | $27M | $29M | $34M | $38M | $31M | |
| Capital Leases | $57M | $15M | $32M | $41M | $50M | $38M | $42M | · | · | · | · | $2M | |
| Other Non-current Liabilities | $0 | $546.0K | $751.0K | $1M | $3M | $752.0K | · | · | · | $2M | $1M | $2M | |
| Total Liabilities | $779M | $754M | $1.04B | $1.20B | $1.22B | $78M | $93M | $56M | $58M | $53M | $58M | $69M | |
| Long-term Debt | · | · | · | $897M | $896M | · | $16M | $15M | $14M | $16M | · | $14M | |
| Total Debt | · | $0 | $490.0K | $2M | $2M | · | $16M | · | · | · | · | · | |
| Common Stock | $302.0K | $294.0K | $268.0K | $227.0K | $221.0K | $192.0K | $153.0K | $150.0K | $116.0K | $93.0K | $80.0K | $74.0K | |
| Paid-in Capital | $2.70B | $2.65B | $2.54B | $2.10B | $2.01B | $1.37B | $1.12B | $1.10B | $966M | $872M | $787M | $736M | |
| Retained Earnings | $-2.70B | $-2.15B | $-1.84B | $-1.53B | $-1.22B | $-1.04B | $-1.07B | $-982M | $-880M | $-788M | $-713M | $-681M | |
| AOCI | $457.0K | $422.0K | $219.0K | $-5M | $-1M | $85.0K | $5.0K | $-36.0K | $-32.0K | $5.0K | $-7.0K | $9.0K | |
| Stockholders' Equity | $5M | $507M | $701M | $563M | $791M | $335M | $55M | $114M | $86M | $85M | $74M | $55M | |
| Liabilities + Equity | $784M | $1.26B | $1.75B | $1.77B | $2.01B | $414M | $148M | $170M | $144M | $138M | $131M | $124M | |
| Shares Outstanding | 301,956,000 | 294,418,000 | 267,744,000 | 226,505,000 | 220,978,000 | 192,294,000 | 153,119,000 | 150,244,000 | 116,277,000 | 92,677,000 | 79,983,000 | 73,927,000 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $7M | $8M | $4M | $4M | $4M | |
| Stock-based Comp | $42M | $71M | $72M | $79M | $73M | $18M | $16M | $23M | $20M | $20M | $14M | $10M | |
| Deferred Tax | $-546.0K | $-205.0K | $-11M | $0 | $-94M | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $369M | $27M | $8M | $913.0K | $0 | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | $13M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | $6M | $-4M | $-17M | $-34M | $528.0K | |
| Operating Cash Flow | $-111M | $-206M | $-259M | $-263M | $-111M | $20M | $-78M | $-66M | $-68M | $-68M | $-48M | $-51M | |
| CapEx | $3M | $6M | $9M | $17M | $6M | $1M | $3M | $2M | $10M | $8M | $3M | $2M | |
| Investing Cash Flow | $115M | $124M | $5M | $116M | $-679M | $-219M | $62M | $-38M | $-2M | $-15M | · | · | |
| Stock Issued | $0 | $0 | $189M | $0 | $32M | $46M | $9M | $10M | $9M | $8M | $7M | $4M | |
| Net Stock Activity | $0 | $0 | $15M | $11M | $32M | $46M | $9M | $10M | $9M | $8M | $7M | $4M | |
| Financing Cash Flow | $3M | $-43M | $109M | $10M | $1.17B | $252M | $27M | $107M | $69M | $66M | · | · | |
| Net Change in Cash | $8M | $-125M | $-146M | $-138M | $380M | · | · | · | $-258.0K | $-17M | $-3M | $10M | |
| Taxes Paid | $481.0K | $256.0K | $140.0K | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-114M | $-212M | $-268M | $-280M | $-117M | $18M | $-81M | $-68M | $-78M | $-76M | $-51M | $-53M | |
| Levered FCF | · | · | $-282M | · | $-125M | · | · | · | · | · | · | · |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 28.6% | 24.2% | 26.3% | 38.2% | 45.1% | 41.3% | 38.0% | 31.9% | 37.1% | 48.7% | 57.6% | 38.6% | |
| Operating Margin | -346.1% | -308.0% | -166.8% | -239.4% | -161.2% | -132.3% | -110.6% | -128.4% | -96.1% | -78.5% | -31.4% | -103.7% | |
| Net Margin | -341.5% | -201.2% | -153.0% | -244.9% | -138.8% | 37.3% | -92.6% | -130.4% | -98.6% | -82.0% | -34.2% | -109.2% | |
| Pretax Margin | -341.3% | -201.0% | -158.7% | -244.9% | -210.6% | · | · | · | · | · | · | · | |
| EBITDA Margin | -346.1% | -308.0% | -166.8% | -239.4% | -161.2% | -132.3% | -110.6% | -119.3% | -87.0% | -74.3% | -27.4% | -96.8% | |
| ROA | -53.4% | -20.6% | -17.5% | -16.7% | -15.0% | 10.5% | -52.9% | -65.2% | -65.4% | -55.3% | -24.8% | -50.7% | |
| ROE | -1634.9% | -64.6% | -41.9% | -52.8% | -22.2% | 12.7% | -158.8% | -83.4% | -108.0% | -94.0% | -49.3% | -106.6% | |
| ROIC | -10360.5% | -93.7% | -46.0% | · | -17.5% | · | · | · | · | · | · | · |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.1 | 7.5 | 7.8 | 3.2 | 15.4 | 9.2 | 1.6 | 4.9 | 3.5 | 3.2 | 2.9 | 3.7 | |
| Quick Ratio | 4.3 | 6.3 | 7.0 | 3.0 | 14.9 | 8.7 | 1.3 | 4.1 | 2.7 | 2.5 | 2.3 | 3.3 | |
| Debt / Equity | · | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.3 | · | · | · | · | · | |
| Interest Coverage | · | · | -23.3 | -20.9 | -16.8 | -391.0 | -38.5 | -41.7 | -30.7 | -22.0 | -10.0 | -22.2 |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.6 | 0.5 | 0.7 | 0.7 | 0.7 | 0.5 | |
| Inventory Turnover | 2.1 | 2.0 | 2.8 | 2.1 | 3.7 | 3.4 | 3.6 | 2.6 | 3.0 | 3.5 | 3.5 | 3.5 | |
| Receivables Turnover | 5.1 | 4.8 | 7.2 | 6.0 | 6.4 | 4.9 | 7.6 | 7.1 | 7.5 | 10.9 | 21.4 | 19.7 |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.02 | $1.72 | $2.62 | $2.49 | $3.58 | $1.74 | $0.36 | $0.76 | $0.74 | $0.91 | $0.92 | $0.74 | |
| Revenue / Share | $0.53 | $0.53 | $0.79 | $0.57 | $0.64 | $0.45 | · | · | · | · | · | · | |
| Cash Flow / Share | $-0.37 | $-0.71 | $-1.02 | $-1.17 | $-0.54 | $0.11 | · | · | · | · | · | · | |
| Cash / Share | $0.21 | $0.19 | $0.67 | $1.44 | $2.08 | $0.42 | $0.19 | $0.13 | $0.14 | $0.18 | $0.42 | $0.49 | |
| Dividend / Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| EPS (TTM) | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 | $0.17 | $-0.55 | $-0.76 | · | · | · | · |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 3.9% | -23.2% | 56.3% | -1.7% | 65.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.6% | 5.7% | 36.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.2% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $160M | $154M | $201M | $128M | $131M | $79M | $91M | $79M | $93M | $91M | $93M | $61M | |
| Net Income TTM | $-546M | $-310M | $-307M | $-314M | $-181M | $29M | $-84M | $-103M | $-92M | $-74M | $-32M | $-66M | |
| Market Cap | $565M | $539M | $2.63B | $1.85B | $4.52B | $4.99B | $787M | $1.11B | $307M | $352M | $1.05B | $580M | |
| Enterprise Value | · | $149M | $2.00B | $1.08B | $3.48B | · | $754M | · | · | · | · | · | |
| P/E | -1.0 | -1.2 | -8.1 | -5.8 | -23.0 | 152.6 | -9.3 | -9.7 | · | · | · | · | |
| P/S | 3.5 | 3.5 | 13.1 | 14.4 | 34.6 | 63.2 | 8.7 | 14.1 | 3.3 | 3.9 | 11.3 | 9.6 | |
| P/B | 105.6 | 1.1 | 3.7 | 3.3 | 5.7 | 14.9 | 14.3 | 9.7 | 3.6 | 4.2 | 14.3 | 10.5 | |
| P / Tangible Book | · | · | · | · | · | 14.9 | · | · | · | · | · | · | |
| P / Cash Flow | -5.1 | -2.6 | -10.1 | -7.0 | -40.7 | 255.8 | -10.0 | -16.7 | -4.5 | -5.2 | -21.9 | -11.3 | |
| P / FCF | -5.0 | -2.5 | -9.8 | -6.6 | -38.6 | 270.2 | -9.7 | -16.3 | -3.9 | -4.6 | -20.6 | -10.9 | |
| EV / EBITDA | · | -0.3 | -6.0 | -3.5 | -16.5 | · | -7.5 | · | · | · | · | · | |
| EV / FCF | · | -0.7 | -7.4 | -3.9 | -29.7 | · | -9.3 | · | · | · | · | · | |
| EV / Revenue | · | 1.0 | 10.0 | 8.4 | 26.7 | · | 8.3 | · | · | · | · | · | |
| Earnings Yield | -97.3% | -86.9% | -12.3% | -17.1% | -4.3% | 0.66% | -10.7% | -10.3% | · | · | · | · |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39M | $37M | $45M | $38M | $40M | $37M | $39M | $40M | $36M | $39M | $58M | $56M | $48M | $39M | $27M | $32M | |
| Cost of Revenue | $26M | $24M | $28M | $23M | $25M | $39M | $29M | $30M | $30M | $28M | $49M | $38M | $32M | $29M | $22M | $19M | |
| Gross Profit | $13M | $13M | $17M | $16M | $15M | $-1M | $10M | $10M | $6M | $11M | $10M | $18M | $16M | $10M | $5M | $14M | |
| R&D Expense | $23M | $20M | $23M | $23M | $23M | $29M | $27M | $26M | $38M | $43M | $45M | $48M | $46M | $49M | $43M | $47M | |
| SG&A Expense | $33M | $31M | $34M | $31M | $36M | $40M | $42M | $44M | $46M | $44M | $46M | $43M | $41M | $40M | $45M | $37M | |
| Operating Expenses | $57M | $21M | $58M | $55M | $60M | $428M | $163M | $74M | $182M | $93M | $97M | $100M | $89M | $101M | $92M | $88M | |
| Operating Income | $-45M | $-8M | $-41M | $-39M | $-45M | $-429M | $-153M | $-64M | $-176M | $-81M | $-88M | $-82M | $-73M | $-91M | $-87M | $-75M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $4M | · | $4M | $4M | $4M | · | $4M | |
| Other Non-op | $2M | $2M | $3M | $3M | $5M | $4M | $4M | $7M | $6M | $7M | $8M | $9M | $9M | $7M | $6M | $1M | |
| Pretax Income | $-45M | $-8M | $-40M | $-38M | $-42M | $-426M | $3M | $-61M | $-173M | $-78M | $-83M | $-78M | $-70M | $-88M | $-84M | $-77M | |
| Income Tax | $58.0K | $184.0K | $202.0K | $383.0K | $35.0K | $-302.0K | $316.0K | $0 | $0 | $0 | $-718.0K | $-11M | $0 | $0 | $0 | $0 | |
| Net Income | $-45M | $-8M | $-40M | $-38M | $-42M | $-426M | $2M | $-61M | $-173M | $-78M | $-82M | $-67M | $-70M | $-88M | $-84M | $-77M | |
| EPS (Basic) | $-0.14 | $-0.03 | $-0.11 | $-0.13 | $-0.14 | $-1.44 | $0.02 | $-0.22 | $-0.64 | $-0.29 | $-0.31 | $-0.26 | $-0.28 | $-0.36 | $-0.37 | $-0.34 | |
| EPS (Diluted) | $-0.14 | $-0.03 | $-0.11 | $-0.13 | $-0.14 | $-1.44 | $-0.44 | $-0.22 | $-0.64 | $-0.29 | $-0.31 | $-0.26 | $-0.28 | $-0.36 | $-0.37 | $-0.34 | |
| Shares (Basic) | 310,655,000 | 305,819,000 | · | 300,844,000 | 300,162,000 | 296,858,000 | · | 272,915,000 | 272,385,000 | 269,578,000 | · | 255,001,000 | 250,070,000 | 242,032,000 | · | 225,123,000 | |
| Shares (Diluted) | 310,655,000 | 305,819,000 | · | 300,844,000 | 300,162,000 | 296,858,000 | · | 272,915,000 | 272,385,000 | 269,578,000 | · | 255,001,000 | 250,070,000 | 242,032,000 | · | 225,123,000 | |
| EBITDA | $-45M | $-8M | · | $-39M | $-45M | $-429M | · | $-64M | $-176M | $-81M | · | $-82M | $-73M | $-91M | · | $-75M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $61M | $56M | $64M | $56M | $55M | $59M | $55M | $78M | $100M | $77M | $180M | $386M | $209M | $354M | $325M | $304M | |
| Short-term Investments | $176M | $220M | $216M | $242M | $260M | $285M | $335M | $393M | $410M | $485M | · | $382M | $621M | $521M | · | $530M | |
| Receivables | $31M | $29M | $35M | $31M | $32M | $32M | $28M | $29M | $32M | $30M | · | $30M | $24M | $30M | · | $23M | |
| Inventory | $61M | $51M | $49M | $53M | $54M | $54M | $59M | $66M | $69M | $67M | · | $68M | $68M | $62M | · | $43M | |
| Prepaid Expense | $10M | $13M | $11M | $12M | $12M | $15M | $19M | $17M | $17M | $17M | · | $15M | $14M | $14M | · | $13M | |
| Current Assets | $339M | $370M | $375M | $394M | $413M | $445M | $496M | $584M | $628M | $677M | · | $882M | $936M | $981M | · | $914M | |
| PP&E (Net) | $27M | $24M | $24M | $22M | $23M | $25M | $31M | $32M | $35M | $37M | · | $40M | $40M | $41M | · | $39M | |
| PP&E (Gross) | · | · | $117M | · | · | · | $112M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $92M | · | · | · | $82M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $318M | $318M | $318M | $318M | $318M | $318M | $318M | $369M | $369M | $462M | · | $464M | $410M | $410M | · | $410M | |
| Intangibles | $13M | $14M | $15M | $16M | $17M | $18M | $390M | $436M | $443M | $450M | · | $462M | $410M | $410M | · | $410M | |
| Other Non-current Assets | $13M | $14M | $9M | $9M | $9M | $9M | $9M | $10M | $10M | $10M | · | $13M | $13M | $13M | · | $1M | |
| Total Assets | $752M | $782M | $784M | $803M | $825M | $861M | $1.26B | $1.45B | $1.51B | $1.67B | · | $1.90B | $1.85B | $1.90B | · | $1.82B | |
| Accounts Payable | $19M | $14M | $21M | $16M | $15M | $14M | $17M | $12M | $17M | $21M | · | $16M | $17M | $17M | · | $13M | |
| Accrued Liabilities | $30M | $34M | $34M | $29M | $27M | $29M | $23M | $19M | $22M | $22M | · | $35M | $27M | $19M | · | $25M | |
| Current Liabilities | $69M | $65M | $73M | $63M | $60M | $67M | $66M | $60M | $78M | $73M | · | $184M | $271M | $266M | · | $82M | |
| Capital Leases | $60M | $59M | $57M | $54M | $52M | $50M | $15M | $17M | $20M | $29M | · | $34M | $37M | $39M | · | $43M | |
| Other Non-current Liabilities | $8M | $8M | $0 | $0 | $0 | $0 | $546.0K | $751.0K | $751.0K | $751.0K | · | $1M | $837.0K | $969.0K | · | $2M | |
| Total Liabilities | $785M | $780M | $779M | $767M | $764M | $769M | $754M | $997M | $1.02B | $1.02B | · | $1.13B | $1.21B | $1.20B | · | $1.19B | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | $897M | · | $897M | |
| Common Stock | $311.0K | $311.0K | $302.0K | $302.0K | $300.0K | $300.0K | $294.0K | $274.0K | $272.0K | $272.0K | · | $258.0K | $250.0K | $250.0K | · | $226.0K | |
| Paid-in Capital | $2.72B | $2.71B | $2.70B | $2.69B | $2.68B | $2.67B | $2.65B | $2.60B | $2.58B | $2.57B | · | $2.52B | $2.33B | $2.31B | · | $2.08B | |
| Retained Earnings | $-2.75B | $-2.70B | $-2.70B | $-2.65B | $-2.62B | $-2.58B | $-2.15B | $-2.15B | $-2.09B | $-1.92B | · | $-1.76B | $-1.69B | $-1.62B | · | $-1.45B | |
| AOCI | $-503.0K | $-147.0K | $457.0K | $415.0K | $267.0K | $381.0K | $422.0K | $2M | $-523.0K | $-306.0K | · | $-2M | $-3M | $-2M | · | $-6M | |
| Stockholders' Equity | $-33M | $2M | $5M | $36M | $61M | $92M | $507M | $453M | $493M | $649M | $701M | $764M | $642M | $692M | $563M | $627M | |
| Liabilities + Equity | $752M | $782M | $784M | $803M | $825M | $861M | $1.26B | $1.45B | $1.51B | $1.67B | · | $1.90B | $1.85B | $1.90B | · | $1.82B | |
| Shares Outstanding | 310,810,000 | 310,487,000 | 301,956,000 | 301,853,000 | 300,350,000 | 300,041,000 | 294,418,000 | 273,812,000 | 272,491,000 | 272,280,000 | 267,744,000 | 258,374,000 | 250,473,000 | 249,803,000 | 226,505,000 | 225,916,000 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $9M | $4M | $10M | $11M | $12M | $9M | $16M | $18M | $17M | $20M | $17M | $20M | $18M | $18M | $18M | $19M | |
| Amort. of Intangibles | · | $1M | $1M | $1M | $1M | $366M | $7M | $7M | $7M | $7M | $7M | $942.0K | $232.0K | $234.0K | $228.0K | $229.0K | |
| Restructuring | · | · | · | · | · | · | · | · | $11M | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-36M | $-45M | $-19M | $-19M | $-29M | $-44M | $-31M | $-45M | $-54M | $-76M | $-58M | $-65M | $-42M | $-95M | $-61M | $-63M | |
| CapEx | $2M | $3M | $861.0K | $-86.0K | $550.0K | $1M | $2M | $-787.0K | $1M | $4M | $2M | $830.0K | $2M | $4M | $5M | $4M | |
| Investing Cash Flow | $40M | $36M | $26M | $19M | $25M | $45M | $58M | $23M | $77M | $-34M | $-67M | $242M | $-99M | $-73M | $80M | $54M | |
| Stock Issued | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $189M | $0 | $-6M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $189M | · | · | |
| Financing Cash Flow | $255.0K | $1M | $0 | $1M | $0 | $2M | $-50M | $812.0K | $-152.0K | $7M | $-82M | $-781.0K | $-5M | $196M | $819.0K | $3M | |
| Net Change in Cash | $5M | $-7M | $7M | $2M | $-4M | $3M | $-23M | $-22M | $22M | $-103M | $-206M | $176M | $-145M | $29M | $21M | $-6M | |
| Free Cash Flow | · | $-48M | · | · | · | $-45M | · | · | · | $-80M | · | · | · | $-98M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-83M | · | · | · | $-102M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 32.4% | 34.5% | · | 41.4% | 36.9% | -3.7% | · | 25.0% | 16.5% | 29.1% | · | 32.1% | 32.7% | 25.1% | · | 41.9% | |
| Operating Margin | -114.4% | -22.5% | · | -101.1% | -112.8% | -1154.5% | · | -160.3% | -488.3% | -209.6% | · | -148.1% | -153.8% | -234.6% | · | -230.9% | |
| Net Margin | -114.7% | -22.3% | · | -98.9% | -105.4% | -1146.8% | · | -151.9% | -481.3% | -201.4% | · | -120.1% | -146.8% | -226.3% | · | -238.2% | |
| Pretax Margin | -114.5% | -21.8% | · | -97.9% | -105.4% | -1147.6% | · | -151.9% | -481.3% | -201.4% | · | -139.3% | -146.8% | -226.3% | · | -238.2% | |
| EBITDA Margin | -114.4% | -22.5% | · | -101.1% | -112.8% | -1154.5% | · | -160.3% | -488.3% | -209.6% | · | -148.1% | -153.8% | -234.6% | · | -230.9% | |
| ROA | -5.7% | -1.0% | · | -3.4% | -3.6% | -33.7% | · | -3.6% | -10.3% | -4.4% | · | -3.6% | -3.8% | -4.6% | · | -4.0% | |
| ROE | -316.5% | -17.6% | · | -15.5% | -15.1% | -115.1% | · | -10.0% | -30.6% | -11.7% | · | -9.6% | -10.5% | -12.3% | · | -10.5% | |
| ROIC | 134.5% | -361.2% | · | -108.8% | -73.0% | -467.7% | · | -14.1% | -35.7% | -12.5% | · | -9.3% | -11.4% | -13.2% | · | · |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.7 | · | 6.2 | 6.9 | 6.7 | · | 9.7 | 8.0 | 9.3 | · | 4.8 | 3.4 | 3.7 | · | 11.2 | |
| Quick Ratio | 3.9 | 4.7 | · | 5.2 | 5.8 | 5.6 | · | 8.3 | 6.9 | 8.1 | · | 4.3 | 3.1 | 3.4 | · | 10.5 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -22.8 | · | -23.0 | -20.6 | -25.1 | · | -20.4 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.5 | 0.5 | · | 0.4 | 0.4 | 0.6 | · | 0.4 | 0.4 | 0.4 | · | 0.7 | 0.6 | 0.6 | · | 0.6 | |
| Receivables Turnover | 1.2 | 1.2 | · | 1.3 | 1.2 | 1.2 | · | 1.3 | 1.3 | 1.3 | · | 2.1 | 1.9 | 1.4 | · | 1.4 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.11 | $0.01 | · | $0.12 | $0.20 | $0.31 | · | $1.65 | $1.81 | $2.38 | · | $2.96 | $2.56 | $2.77 | · | $2.77 | |
| Revenue / Share | $0.13 | $0.12 | · | $0.13 | $0.13 | $0.13 | · | $0.15 | $0.13 | $0.14 | · | $0.22 | $0.19 | $0.16 | · | $0.14 | |
| Cash Flow / Share | · | $-0.15 | · | · | · | $-0.15 | · | · | · | $-0.28 | · | · | · | $-0.39 | · | · | |
| Cash / Share | $0.20 | $0.18 | · | $0.19 | $0.18 | $0.20 | · | $0.28 | $0.37 | $0.28 | · | $1.49 | $0.84 | $1.42 | · | $1.35 | |
| EPS (TTM) | $-0.41 | $-0.41 | · | $-2.15 | $-2.24 | $-2.74 | · | $-1.46 | $-1.50 | $-1.14 | · | $-1.27 | $-1.35 | $-1.39 | · | $-1.34 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $159M | $160M | · | $155M | $156M | $152M | · | $173M | $189M | $200M | · | $170M | $146M | $134M | · | $137M | |
| Net Income TTM | $-131M | $-129M | · | $-504M | $-526M | $-658M | · | $-394M | $-400M | $-297M | · | $-309M | $-319M | $-321M | · | $-299M | |
| Market Cap | $522M | $410M | · | $386M | $372M | $354M | · | $465M | $373M | $1.02B | · | $2.16B | $3.33B | $2.89B | · | $1.31B | |
| P/E | -4.1 | -3.2 | · | -0.6 | -0.6 | -0.4 | · | -1.2 | -0.9 | -3.3 | · | -6.6 | -9.9 | -8.3 | · | -4.3 | |
| P/S | 3.3 | 2.6 | · | 2.5 | 2.4 | 2.3 | · | 2.7 | 2.0 | 5.1 | · | 12.7 | 22.8 | 21.6 | · | 9.6 | |
| P/B | -15.7 | 173.2 | · | 10.7 | 6.1 | 3.9 | · | 1.0 | 0.8 | 1.6 | · | 2.8 | 5.2 | 4.2 | · | 2.1 | |
| P / Cash Flow | · | -9.2 | · | · | · | -8.0 | · | · | · | -13.5 | · | · | · | -30.5 | · | · | |
| Earnings Yield | -24.4% | -31.1% | · | -168.0% | -180.7% | -232.2% | · | -85.9% | -109.5% | -30.4% | · | -15.2% | -10.2% | -12.0% | · | -23.1% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $160M | $154M | $201M | $128M | $131M |
| Marża Brutto % | 28.6% | 24.2% | 26.3% | 38.2% | 45.1% |
| Marża Operacyjna % | -346.1% | -308.0% | -166.8% | -239.4% | -161.2% |
| Zysk netto | $-546M | $-310M | $-307M | $-314M | $-181M |
| Rozwodniony EPS | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | · | 0.0 | 0.0 | 0.0 | 0.0 |
| Wskaźnik bieżący | 5.1 | 7.5 | 7.8 | 3.2 | 15.4 |
| Wskaźnik Szybkości | 4.3 | 6.3 | 7.0 | 3.0 | 14.9 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-114M | $-212M | $-268M | $-280M | $-117M |
Właściciele instytucjonalni (13F) 244 emitenci · $360.0M łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Posiadacze
244
Wartość posiadanych akcji
$360.0M
Nowe pozycje
24
Zamknięte pozycje
28
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 24 (-30 vs poprzedni kw.) | 28 (-2 vs poprzedni kw.) | 72 (+14 vs poprzedni kw.) | 80 (+4 vs poprzedni kw.) | +4.3M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $54 330 444 | 32 339 550 | 15,09% | Akcje |
| ARK Investment Management LLC | $50 032 778 | 29 781 416 | 13,90% | Akcje |
| SOFTBANK GROUP CORP. | $34 358 638 | 20 451 570 | 9,54% | Akcje |
| VANGUARD GROUP INC | $31 859 776 | 17 037 314 | 8,85% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $22 508 529 | 13 397 934 | 6,25% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $12 782 429 | 7 606 518 | 3,55% | Akcje |
| Sumitomo Mitsui Trust Group, Inc. | $10 096 321 | 6 009 715 | 2,80% | Akcje |
| Amova Asset Management Americas, Inc. | $10 036 224 | 6 009 715 | 2,79% | Akcje |
| STATE STREET CORP | $10 014 774 | 5 961 175 | 2,78% | Akcje |
| Point72 Asset Management, L.P. | $8 042 664 | 4 787 300 | 2,23% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $7 127 566 | 4 242 599 | 1,98% | Akcje |
| D. E. Shaw & Co., Inc. | $7 069 686 | 4 208 146 | 1,96% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $6 656 903 | 3 962 442 | 1,85% | Akcje |
| Point72 (DIFC) Ltd | $5 465 775 | 4 270 137 | 1,52% | Akcje |
| GOLDMAN SACHS GROUP INC | $5 426 210 | 3 229 887 | 1,51% | Akcje |
| CITADEL ADVISORS LLC | $4 781 117 | 2 845 903 | 1,33% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $4 488 819 | 2 671 916 | 1,25% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4 455 861 | 2 652 298 | 1,24% | Akcje |
| NORTHERN TRUST CORP | $3 952 681 | 2 352 786 | 1,10% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $3 675 213 | 2 187 627 | 1,02% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3 577 162 | 2 129 263 | 0,99% | Akcje |
| Longaeva Partners L.P. | $3 558 628 | 2 118 231 | 0,99% | Akcje |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $2 846 837 | 1 694 546 | 0,79% | Akcje |
| Birchview Capital, LP | $2 268 000 | 1 350 000 | 0,63% | Akcje |
| BANK OF AMERICA CORP /DE/ | $2 264 860 | 1 348 131 | 0,63% | Akcje |
| Invesco Ltd. | $2 179 114 | 1 297 091 | 0,61% | Akcje |
| AQR CAPITAL MANAGEMENT LLC | $2 178 430 | 1 296 684 | 0,61% | Akcje |
| Nuveen, LLC | $1 718 830 | 1 023 113 | 0,48% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $1 623 216 | 966 200 | 0,45% | Akcje |
| BOURNE LENT ASSET MANAGEMENT INC | $1 584 332 | 943 055 | 0,44% | Akcje |
| TWO SIGMA ADVISERS, LP | $1 547 425 | 827 500 | 0,43% | Akcje |
| HHLR ADVISORS, LTD. | $1 543 739 | 918 892 | 0,43% | Akcje |
| UBS Group AG | $1 500 475 | 893 140 | 0,42% | Akcje |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $1 358 616 | 808 700 | 0,38% | Akcje |
| Bank of New York Mellon Corp | $1 289 512 | 767 567 | 0,36% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $1 277 135 | 759 783 | 0,35% | Akcje |
| Casdin Capital, LLC | $1 215 929 | 723 767 | 0,34% | Akcje |
| TUDOR INVESTMENT CORP ET AL | $1 150 308 | 684 707 | 0,32% | Akcje |
| XTX Topco Ltd | $1 073 322 | 638 882 | 0,30% | Akcje |
| Numerai GP LLC | $1 044 068 | 621 469 | 0,29% | Akcje |
| CARRET ASSET MANAGEMENT, LLC | $1 008 235 | 600 140 | 0,28% | Akcje |
| Man Group plc | $1 003 521 | 597 334 | 0,28% | Akcje |
| Russell Investments Group, Ltd. | $1 002 694 | 596 843 | 0,28% | Akcje |
| Balyasny Asset Management L.P. | $948 090 | 564 339 | 0,26% | Akcje |
| PEAK6 LLC | $933 327 | 555 552 | 0,26% | Akcje |
| Vestmark Advisory Solutions, Inc. | $803 384 | 478 205 | 0,22% | Akcje |
| MORGAN STANLEY | $802 664 | 477 776 | 0,22% | Akcje |
| ArrowMark Colorado Holdings LLC | $786 882 | 468 382 | 0,22% | Akcje |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $741 954 | 441 639 | 0,21% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $673 008 | 400 600 | 0,19% | Opcja sprzedaży |
Aktywiści i właściciele 5%+ 1 akcja
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Magnetar Financial LLC, Magnetar Capital Partners LP, Supernova Management LLC, Alec N. Litowitz ×3 zgłoszenia | 29 sierpnia 2019 | · | Pierwotne zgłoszenie | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 30 insiderów · 6 dyrektorzy generalni · 11 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Mark Van Oene | President & CEO | 17 sierpnia 2026 S | 2 705 853 | 0 | 4 | $-335 122 |
| Susan K Barnes | EVP, CFO and PAO | 19 lutego 2020 S | 874 812 | 0 | 0 | $0 |
| James Michael Phillips | SVP, Research & Development | 24 marca 2020 S | 249 220 | 0 | 0 | $0 |
| Kevin P Corcoran | SVP, Market Development | 24 listopada 2017 M | 158 174 | 0 | 0 | $0 |
| Michael Glynn | Chief Commercial Officer | 15 lutego 2012 A | · | 0 | 0 | $0 |
| Stephen W Turner | VP & Chief Technology Officer | 11 lipca 2011 J | 1 093 063 | 0 | 0 | $0 |
| Christopher Gibson | Dyrektor | 3 czerwca 2026 A | 111 386 | 0 | 0 | $0 |
| Hannah Valantine | Dyrektor | 3 czerwca 2026 A | 22 821 | 0 | 0 | $0 |
| William W. Ericson | Dyrektor | 3 czerwca 2026 A | 41 616 | 0 | 0 | $0 |
| Christopher M Smith | Dyrektor | 3 czerwca 2026 A | 54 099 | 0 | 0 | $0 |
| Marshall Mohr | Dyrektor | 3 czerwca 2026 A | 132 821 | 0 | 0 | $0 |
| Randall S Livingston | Dyrektor | 3 czerwca 2026 A | 22 821 | 0 | 0 | $0 |
| Kathy Ordonez | Dyrektor | 3 czerwca 2026 A | 403 037 | 0 | 0 | $0 |
| John F Milligan | Dyrektor | 3 czerwca 2026 A | 132 821 | 0 | 0 | $0 |
| David B. Singer | Dyrektor | 13 czerwca 2012 A | · | 0 | 0 | $0 |
| Susan E Siegel | Dyrektor | 13 czerwca 2012 A | 65 000 | 0 | 0 | $0 |
| Hugh C Martin | Dyrektor | 3 lutego 2012 M | 342 458 | 0 | 0 | $0 |
| James R Gibson II | · | 1 kwietnia 2026 S | 1 245 663 | 0 | 1 | $-120 813 |
| Michele Farmer | · | 3 marca 2026 S | 305 948 | 0 | 3 | $-84 510 |
| Christian O Henry | · | 3 marca 2026 S | 3 581 813 | 0 | 3 | $-772 728 |
| Lucy Shapiro | · | 4 czerwca 2025 A | 22 821 | 0 | 0 | $0 |
| Susan G. Kim | · | 30 września 2024 S | 695 654 | 0 | 0 | $0 |
| Jeff Eidel | · | 19 sierpnia 2024 S | 869 730 | 0 | 0 | $0 |
| David W Meline | · | 18 czerwca 2024 A | 57 116 | 0 | 0 | $0 |
| David Botstein | · | 24 maja 2023 A | 0 | 0 | 0 | $0 |
| Peter Fromen | · | 2 marca 2022 A | 190 280 | 0 | 0 | $0 |
| Michael Hunkapiller | · | 26 lutego 2021 M | 848 405 | 0 | 0 | $0 |
| Eric Schaefer | · | 22 lutego 2021 S | 88 474 | 0 | 0 | $0 |
| BYERS BROOK H | · | 17 maja 2016 A | 110 504 | 0 | 0 | $0 |
| Brian B Dow | · | 2 marca 2015 P | 18 119 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 21 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,97% | 88 548 SH | 2 października 2026 | Dziennie |
| ARKG · ARK ETF Trust | 0,96% | 10 630 263 NS | 31 lipca 2026 | N-PORT |
| IDNA · iShares Trust | 0,35% | 711 655 SH | 11 września 2026 | Dziennie |
| ARKK · ARK ETF Trust | 0,32% | 12 810 378 NS | 31 lipca 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,09% | 981 246 SH | 2 października 2026 | Dziennie |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,05% | 21 993 SH | 2 października 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,03% | 280 941 SH | 19 sierpnia 2026 | Dziennie |
| IBB · iShares Trust | 0,03% | 2 192 352 SH | 11 września 2026 | Dziennie |
| IWO · iShares Trust | 0,02% | 2 473 318 SH | 11 września 2026 | Dziennie |
| RSSL · Global X Funds | 0,01% | 134 834 NS | 31 lipca 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 7 217 251 SH | 11 września 2026 | Dziennie |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 3 579 782 SH | 19 sierpnia 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 1 624 029 SH | 19 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,01% | 727 094 SH | 19 sierpnia 2026 | Dziennie |
| ITOT · iShares Trust | 0,00% | 431 328 SH | 11 września 2026 | Dziennie |
| IWV · iShares Trust | 0,00% | 69 680 SH | 9 września 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 9 535 565 SH | 19 sierpnia 2026 | Dziennie |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 17 047 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 22 805 SH | 19 sierpnia 2026 | Dziennie |
| DFAC · Dimensional ETF Trust | 0,00% | 8 144 NS | 31 lipca 2026 | N-PORT |
| IWN · iShares Trust | · | 207 024 SH | 11 września 2026 | Dziennie |
PACB Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
ocena · 14 analityków
KUP
Średni cel
$2.00
-21,3%
4 28,6%
Mocne kupno
5 35,7%
Kup
4 28,6%
Trzymaj
1 7,1%
Sprzedaj
0 0,0%
Mocna sprzedaż
12-miesięczny cel cenowy
7 analityków · 2026-10-02Średnia cel $2.16 -15,1%
Teraz
Aktualna cena $2.54
Niski$1.25
Średnia$2.16
Wysoki$3.00
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| PACB | $565M | -1.0 | 3.9% | -341.5% | -1634.9% | 28.6% |
| BLFS | · | -241.8 | 28.9% | · | · | · |
| PSNL | $816M | -8.7 | -17.7% | -116.7% | -36.0% | · |
| AZTA | $1.32B | -23.5 | 3.5% | -9.4% | -3.3% | 45.5% |
| CYRX | $479M | 6.9 | 12.4% | 44.4% | 15.3% | 47.1% |
| DNA | $484M | -1.5 | -25.1% | -183.8% | -55.8% | · |
| CTKB | $649M | 505.0 | 0.52% | -33.0% | -18.5% | 51.8% |
| MLAB | $489M | 73.1 | 3.4% | 2.7% | 3.7% | 63.5% |
| OABI | · | · | · | · | · | · |
| TKNO | $204M | -11.9 | 7.3% | -42.6% | -23.8% | 33.2% |
| QSI | · | · | · | · | · | · |
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Źródło: SEC 10-Q złożone Sie 6, 2026